Peters A M, Saverymuttu S H, Bell R N, Lavender J P
Scand J Haematol. 1985 Feb;34(2):111-20. doi: 10.1111/j.1600-0609.1985.tb02242.x.
The kinetics of autologous granulocytes, separated from whole blood and labelled with 111In-tropolonate with continuous maintenance in plasma, have been studied in man, using a gamma camera and computer, with the aim of quantifying the distribution of the marginating granulocyte pool (MGP). We have used 3 approaches: dynamic gamma camera imaging immediately following i.v. injection of labelled cells, comparison of the activity signal from 111In-granulocytes with that from previously injected 111In-labelled red cells and absolute quantification of 111In present in liver, spleen and blood. Deconvolution analysis of the hepatic and peripheral blood time activity curves indicated that hepatic granulocyte transit time was 2.5 +/- SE 0.14 min. By comparison with 111In red cells, hepatic transit time was calculated to be 7.4 +/- SE 0.82 that of red cells, which, assuming an hepatic red cell content of 6% that of the total red cell mass, is equivalent to a transit time of 1.8 min. By comparison with 111In red cells, lung granulocyte transit time as a factor of red cel transit time was 5.4 +/- SE 0.7 at 5 min and 2.5 +/- SE 0.13 at 40 min after granulocyte injection. Using these kinetic data, in combination with previously published values for splenic granulocyte transit time, it was calculated that, 5 min after injection, the MGP accounted for 54% of the total blood granulocyte pool (TBGP), was 90% filled, and was distributed between spleen (19%), liver (26%), lung (33%) and the remainder of the body (22%). At 40 min, the MGP accounted for 60% of the TBGP, had equilibrated with the circulating granulocyte pool (CGP), and was distributed between the spleen, liver, lung and remainder of the body according to the following respective percentages: 35, 25, 10 and 30. The total granulocyte contents of the spleen and liver calculated on the basis of the kinetic data were 21% and 22% respectively and in broad agreement with the values, 34 and 23% respectively, calculated from quantitative scanning. It was concluded that about 70% of the body's MGP was present in the spleen, liver and lung. If the MGP is itself 60% of the TBGP then only about 18% of the TBGP marginates in extra-hepatosplenopulmonary sites.
从全血中分离出的自体粒细胞，用111铟-托酚酮标记，并在血浆中持续保存，其动力学已在人体中进行了研究。使用γ相机和计算机，目的是量化边缘粒细胞池（MGP）的分布。我们采用了3种方法：静脉注射标记细胞后立即进行动态γ相机成像，比较111铟-粒细胞的活性信号与先前注射的111铟标记红细胞的活性信号，以及对肝脏、脾脏和血液中存在的111铟进行绝对定量。对肝脏和外周血时间-活性曲线的去卷积分析表明，肝脏粒细胞通过时间为2.5±标准误0.14分钟。与111铟红细胞相比，计算得出肝脏通过时间为红细胞通过时间的7.4±标准误0.82倍，假设肝脏红细胞含量为总红细胞质量的6%，则相当于通过时间为1.8分钟。与111铟红细胞相比，粒细胞注射后5分钟时，肺粒细胞通过时间与红细胞通过时间的比值为5.4±标准误0.7，40分钟时为2.5±标准误0.13。利用这些动力学数据，结合先前发表的脾脏粒细胞通过时间值，计算得出注射后5分钟时，MGP占总血粒细胞池（TBGP）的54%，填充率为90%，分布于脾脏（19%）、肝脏（26%）、肺（33%）和身体其他部位（22%）。40分钟时，MGP占TBGP的60%，已与循环粒细胞池（CGP）达到平衡，并按以下各自百分比分布于脾脏、肝脏、肺和身体其他部位：35%、25%、10%和30%。根据动力学数据计算得出的脾脏和肝脏总粒细胞含量分别为21%和22%，与定量扫描计算得出的值（分别为34%和23%）大致相符。得出的结论是，人体约70% 的MGP存在于脾脏、肝脏和肺中。如果MGP本身占TBGP的60%，那么只有约18% 的TBGP在肝脾肺外部位边缘化。
